Bristol-Myers Squibb Financials
| BMYMP Stock | USD 1,010 9.00 0.90% |
Bristol-Myers |
Understanding current and past Bristol-Myers Squibb Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bristol-Myers Squibb's financial statements are interrelated, with each one affecting the others. For example, an increase in Bristol-Myers Squibb's assets may result in an increase in income on the income statement.
Bristol-Myers Squibb Stock Summary
Bristol-Myers Squibb competes with Novartis, Bayer AG, Astellas Pharma, Roche Holding, and Astellas Pharma. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US1101222073 |
| Business Address | 345 Park Avenue |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Major |
| Benchmark | Dow Jones Industrial |
| Website | www.bms.com |
| Phone | 212 546 4000 |
| Currency | USD - US Dollar |
Bristol-Myers Squibb Key Financial Ratios
Bristol-Myers Squibb's financial ratios allow both analysts and investors to convert raw data from Bristol-Myers Squibb's financial statements into concise, actionable information that can be used to evaluate the performance of Bristol-Myers Squibb over time and compare it to other companies across industries.Bristol-Myers Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bristol-Myers Squibb's current stock value. Our valuation model uses many indicators to compare Bristol-Myers Squibb value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol-Myers Squibb competition to find correlations between indicators driving Bristol-Myers Squibb's intrinsic value. More Info.Bristol Myers Squibb is the top company in revenue category among its peers. It also is number one stock in ebitda category among its peers totaling about 0.43 of EBITDA per Revenue. The ratio of Revenue to EBITDA for Bristol Myers Squibb is roughly 2.31 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol-Myers Squibb's earnings, one of the primary drivers of an investment's value.Bristol Myers Squibb Systematic Risk
Bristol-Myers Squibb's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bristol-Myers Squibb volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Bristol Myers Squibb correlated with the market. If Beta is less than 0 Bristol-Myers Squibb generally moves in the opposite direction as compared to the market. If Bristol-Myers Squibb Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bristol Myers Squibb is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bristol-Myers Squibb is generally in the same direction as the market. If Beta > 1 Bristol-Myers Squibb moves generally in the same direction as, but more than the movement of the benchmark.
Bristol-Myers Squibb March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bristol-Myers Squibb help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bristol Myers Squibb. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bristol Myers Squibb based on widely used predictive technical indicators. In general, we focus on analyzing Bristol-Myers Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bristol-Myers Squibb's daily price indicators and compare them against related drivers.
| Downside Deviation | 8.28 | |||
| Information Ratio | 0.0687 | |||
| Maximum Drawdown | 32.9 | |||
| Value At Risk | (8.24) | |||
| Potential Upside | 12.78 |
Additional Tools for Bristol-Myers Pink Sheet Analysis
When running Bristol-Myers Squibb's price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.